Residual disease kinetics among patients with high-risk factors treated with first-line fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O): The Glow Study

Presented at the most recent ASH meeting, this analysis of the GLOW study demonstrated that undetectable minimal residual disease rates were better for all-oral, once-daily, fixed-duration ibrutinib plus venetoclax compared with chlorambucil plus obinutuzumab. Patients with unmutated IGHV demonstrated higher rates of MRD negativity compared to patients with mutated IGHV, and disease progression within the first 18 months after treatment with fixed duration ibrutinib plus venetoclax was uncommon. Importantly, after a median follow up of 34 months, IGHV mutation status did not impact PFS in the fixed duration ibrutinib plus venetoclax arm, however, unmutated IGHV was associated with shorter PFS in patients treated with chlorambucil plus obinutuzumab.